Clinical Genomics' fecal occult blood test InSure FIT was more effective than two other leading tests in a study of 1,000-plus people, according to a study published in The American Journal of Gastroenterology.
Study researchers compared InSure FIT, OC FIT-chek and Hemoccult II Sensa in 1,006 asymptomatic patients between 50 and 75 years, who also received a screening colonoscopy.
Researchers found that InSure FIT was statistically significantly more sensitive than both OC FIT-check and Hemoccult II Sensa.
Concerning advanced colorectal neoplasia, InSure FIT had the highest detection rate at 26.3 percent, followed by OC FIT-chek at 15.1 percent and Hemoccult II Sensa at 7.4 percent.
Specificities were high for all three tests.
Researchers concluded, "Our results suggest that some FITs are more sensitive than the HS-gFOBT Hemoccult II Sensa, but these results need to be confirmed in larger asymptomatic populations. Comparisons between the FITs examined in this study and other FITs are needed to determine the best tests for population screening."